Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diphenylpyraline→

Diphenylpyraline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
147-20-6
Molecular formula
C19H23NO
Molecular weight
281.39202 g/mol
Drug class
First-generation H1 antihistamineantiallergic agent
Mechanism of action
Competitively antagonises histamine H1 receptors, reducing allergic symptoms including itching, sneezing and rhinorrhoea. It may also have sedative and anticholinergic effects.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, urticaria and pruritic skin disorders in countries where diphenylpyraline remains authorised; current availability is limited and jurisdiction-specific

Sources: NLM MeSH — Diphenylpyraline · PubMed — Diphenylpyraline antihistamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diphenylpyraline Environmental Risk Assessment (ERA) (the Diphenylpyraline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.